Detailed contribution information

Back to list

Contribution title Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with Chronic Hand Eczema (CHE): results of the Phase 3 open-label extension DELTA-3 trial
Authors
  1. Melinda Gooderham Department of Medicine, Queens University, Kingston, Ontario, Canada Presenter
  2. Sonja Molin SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada
  3. Robert Bissonnette Innovaderm Research, Montreal, Quebec, Canada
  4. Margitta Worm Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Germany
  5. Marie-Noëlle Crépy Department of Dermatology, University Hospital of Centre of Paris, Cochin Hospital, AP-HP, Paris, France
  6. Luca Stingeni Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
  7. Richard B Warren Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK
  8. Marie Louise Oesterdal LEO Pharma A/S, Ballerup, Denmark
  9. Cherry Lou Balita-Crisostomo 12LEO Pharma A/S
  10. Sibylle Schliemann
  11. Tove Agner Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
Form of presentation Poster
Topic
  • 1.1 Inflammatory and immune-mediated dermatoses